CD38-Directed Therapies for Management of Multiple Myeloma

The survival outcomes for multiple myeloma have improved several-fold in the past two decades, primarily due to the introduction of therapies with novel mechanisms of action including immunomodulatory agents, proteasome inhibitors, stem cell transplant and monoclonal antibodies in the schema of ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashmi, Hamza, Husnain, Muhammad, Khan, Ali, Usmani, Saad Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254545/
https://www.ncbi.nlm.nih.gov/pubmed/34235096
http://dx.doi.org/10.2147/ITT.S259122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254545/
https://www.ncbi.nlm.nih.gov/pubmed/34235096
http://dx.doi.org/10.2147/ITT.S259122

Ejemplares similares